Conferences
49Scientific congress presentations, newest first.
- NEGATIVE RESULTS
aTyr's efzofitimod misses again on steroids in sarcoidosis lung subgroup
A 44-patient post hoc slice of the failed Phase 3 EFZO-FIT trial shows an FVC gain that is now anchoring aTyr's next registrational study, not the original steroid-sparing goal.
NCT05415137 - Conference Presentation
Profound Medical to present CAPTAIN safety data on TULSA vs. prostatectomy at SRS2026
The randomized trial's primary completion date has already slipped a year, and the July 26 session is billed as safety outcomes, not the efficacy result investors are waiting on.
NCT05027477 - Conference Presentation
Profound Medical's CAPTAIN trial to present TULSA safety data vs prostatectomy
The randomized CAPTAIN trial presents primary safety outcomes for the TULSA ablation procedure against radical prostatectomy, four years into a trial whose completion date has already slipped a year.
NCT05027477 - Conference Presentation
Merck to present ISLEND-2 Week 48 data confirming weekly ISL/LEN met endpoint
The Phase 3 readout already showed the switch regimen held HIV-1 suppression at Week 48; AIDS 2026 delivers the full efficacy and safety data behind that result.
NCT06630299 - Conference Presentation
Merck to unveil Week 24 data on weekly islatravir/ulonivirine at AIDS 2026
The Phase 2b readout tests whether a once-weekly pill can hold viral suppression as well as daily BIC/FTC/TAF, Merck's established switch regimen.
NCT06891066 - Conference Presentation
Gilead's weekly islatravir/lenacapavir met HIV suppression goal versus Biktarvy
ISLEND-1's Week 48 data, already disclosed in June, head to AIDS 2026 on July 29 as Merck and Gilead push once-weekly oral dosing against daily standards of care.
NCT06630286 - Conference Presentation
Annexon's ARCHER data will pick who enrolls in pivotal ARCHER II readout
A Phase 2 baseline-characteristics analysis of vonaprument in geographic atrophy sets up the enrollment logic behind Annexon's 659-patient Phase 3 trial, due to read out in the fourth quarter of 2026.
NCT04656561 - Conference Presentation
Alpha Tau to present full HNSCC data after 75% ORR interim readout
The AHNS podium talk on July 21 will report complete results from a 48-patient Israeli study pairing Alpha DaRT radiation seeds with pembrolizumab in elderly head and neck cancer, building on an 8-patient interim look that showed a 75% objective response rate.
NCT05047094 - Conference Presentation
Alkeus to present Phase 2 TEASE gildeuretinol data alongside Phase 3 design at ASRS
The July 18 presentation covers a Phase 2 tolerability study built around a safety endpoint, with Alkeus using the session to preview the Phase 3 NORTHSTAR design that will test disease-modifying efficacy.
NCT02402660 - Conference Presentation
Enterome's EO2463 vaccine posts 74% ORR in lymphoma combination cohort
Updated SIDNEY data due at the Pan Pacific Lymphoma Conference will test whether an off-the-shelf peptide vaccine can hold its interim response and durability numbers as more patients mature.
NCT04669171 - Conference Presentation
Nektar to present 36-week rezpegaldesleukin maintenance data in H2 2026
REZOLVE-AD's Week 16 primary readout already showed EASI reduction versus placebo; the pending presentation extends that signal through 36 weeks as Nektar moves the drug into Phase 3.
NCT06136741 - Conference Presentation
REGENXBIO to present 2.5-year ALTITUDE gene therapy data as NAAVIGATE enrolls
The July ASRS presentation extends two-year dose-level-3 data already tied to no intraocular inflammation, as AbbVie's larger Phase IIb/III NAAVIGATE trial tests the same suprachoroidal dose in a sham-controlled design.
NCT04567550 - Conference Presentation
Ocugen to detail OCU410 gene therapy imaging and safety data at ASRS
The July 17 presentation extends Ocugen's preliminary ArMaDa readout with imaging and safety detail, testing whether the 31% lesion-growth reduction holds up in a subretinal gene therapy field with no approved disease-modifying option.
NCT06018558 - Conference Presentation
Ollin presents head-to-head OLN324 vs. Vabysmo data at ASRS ahead of Phase 3
The Phase 1b JADE readout, already disclosed in March, gets an oral presentation on anatomic and vision outcomes as Ollin heads toward Phase 3 trials in DME and wet AMD.
NCT07484074 - Conference Presentation
Cognition's zervimesine slowed DLB hallucinations 89%, FDA calls it approvable
New Phase 2 SHIMMER data due at AAIC in July extend a placebo-controlled result that already secured FDA alignment on a Phase 3 psychosis trial for a disease with no approved therapy.
NCT05225415 - Conference Presentation
Eisai brings AHEAD 3-45 retention data to AAIC, not efficacy results
The Phase 3 prevention trial in preclinical Alzheimer's will show participant retention and engagement data at AAIC in July, with the amyloid-PET primary endpoint still years from readout.
NCT04468659 - Conference Presentation
REGENXBIO to present five-year RGX-314 wet AMD gene therapy data in July
The ASRS presentation extends a durability record already tied to reduced anti-VEGF injections, arriving as AbbVie's subretinal pivotal trials near a Q4 2026 readout.
NCT03066258 - AMBIGUOUS RESULTS
Codex Labs to present 95% SCORAD drop in open-label pediatric eczema pilot
The Silicon Valley skincare company will show an 80-child, single-arm result at a pediatric dermatology meeting, a descriptive signal rather than a controlled comparison against standard eczema care.
NCT07670676 - Conference Presentation
Nervonik to present nerve-sensing data from 8-patient study at ASPN 2026
The device recorded electrical nerve signals during peripheral nerve stimulation in a small feasibility study, a step toward closed-loop pain therapy still years from a registrational trial.
NCT06772142 - Conference Presentation
Acumen's AAIC poster is patient survey data, not ALTITUDE-AD topline results
The July 14 presentation covers patient perspectives from the trial population, while the actual iADRS readout for sabirnetug is not due until the trial's October 2026 primary completion.
NCT06335173 - Conference Presentation
Organon to show pooled ADORING data on VTAMA in AD across pediatric, adult ages
The July 22 presentation recasts already-approved Phase 3 results by age subgroup rather than adding a new clinical readout for the AhR agonist cream.
NCT05032859 - Conference Presentation
CervoMed posts first 80 mg neflamapimod data in Lewy body dementia
The Phase 2 dose-finding trial met its safety and pharmacokinetic goals, and CervoMed says the result sets the dose for a planned Phase 3 program in a disease with no approved treatment.
NCT06815965 - Conference Presentation
NewAmsterdam extends obicetrapib's LDL story into an Alzheimer's biomarker signal
A poster at AAIC 2026 builds on a prespecified BROADWAY biomarker analysis that already showed a p-tau217 reduction at 12 months, positioning the LDL-lowering drug for a disease it was never designed to treat.
NCT05142722 - Conference Presentation
Belite Bio's DRAGON data head to ASRS as first Phase 3 win in Stargardt disease
Tinlarebant already cut Stargardt lesion growth 35.7% versus placebo in the completed DRAGON trial; the ASRS presentation puts that result before retina specialists for the first time.
NCT05244304 - Conference Presentation
NewAmsterdam extends obicetrapib's cardiovascular data into an Alzheimer's biomarker signal
Posters at AAIC 2026 build on BROADWAY's prespecified p-tau217 finding, testing whether a CETP inhibitor built for cholesterol has a case in Alzheimer's prevention.
NCT05142722 - AMBIGUOUS RESULTS
Alzheon presses ALZ-801 case with 4-year data after Phase 3 miss
The AAIC posters lean on long-term extension biomarkers and imaging from a completed Phase 2 trial to reframe an oral amyloid drug whose placebo-controlled Phase 3 did not hit its primary endpoint.
NCT04693520 - Conference Presentation
Cognition Therapeutics to detail Phase 3 plan for CT1812 in DLB psychosis
The July 16 fireside chat centers on a registrational Lewy body dementia psychosis study built on Phase 2 SHIMMER data, not new results from the ongoing Alzheimer's trial.
NCT05531656 - Conference Presentation
Nocion to detail ASPIRE cough trial status as Q3 readout nears
A July 16 poster update on taplucainium precedes topline data from the placebo-controlled Phase 2b trial, the first U.S. cough therapy readout to test a charged sodium channel blocker.
NCT06504446 - Conference Presentation
Alkeus to detail Phase 3 gildeuretinol design for Stargardt disease at ASRS
The presentation pairs Phase 2 TEASE safety and efficacy data with the design of the enrolling Phase 3 NORTHSTAR trial, the study that will test whether gildeuretinol slows lesion growth against placebo.
NCT07419334 - Conference Presentation
Mighty Therapeutics details FDA-mandated Phase 4 trial confirming elamipretide in Barth syndrome
The July 22 conference presentation covers a 48-patient confirmatory trial required after FORZINITY's accelerated approval, not a new efficacy readout.
NCT07531251 - Conference Presentation
Astellas to present GATHER1 driving-eligibility and EZ integrity data for IZERVAY at ASRS
New biomarker and functional analyses from the completed GATHER1 trial extend evidence behind the only approved complement inhibitor for geographic atrophy.
NCT02686658 - Conference Presentation
Astellas to unveil first Phase 1b look at stem cell therapy ASP7317 in GA
The July 15 ASRS presentation offers the first preliminary human data on early visual improvement and safety signals for a stem cell-derived retinal implant in geographic atrophy.
NCT03178149 - Conference Presentation
Ollin details OLN324's head-to-head edge over faricimab in wAMD at ASRS
The Phase 1b JADE data Ollin previewed in March get their full airing at ASRS, setting up global Phase 3 trials in wet AMD and diabetic macular edema later this year.
NCT07484074 - Conference Presentation
Biogen to unveil first CELIA data on tau-targeting BIIB080 at AAIC
The Phase 2 CELIA study tests whether reducing tau production with an antisense drug moves CDR-SB in early Alzheimer's, a mechanism with no approved precedent.
NCT05399888 - Conference Presentation
Ocugen to detail 1-year OCU410 gene therapy data for geographic atrophy at ASRS
The presentation follows a 31% reduction in lesion growth reported at 12 months, and the ASRS talk will show whether that effect and safety hold at one year.
NCT06018558 - Conference Presentation
SPR to present 12-month RESET trial results for SPRINT PNS in back pain
The randomized RESET trial tested 60-day peripheral nerve stimulation against usual care in chronic low back pain, with 12-month outcomes reaching a public podium for the first time.
NCT04246281 - Conference Presentation
Kura to show longer follow-up on darlifarnib-cabozantinib in kidney cancer
The July 24 presentation extends Phase 1a data already showing a 44% response rate in pretreated patients, this time in cabozantinib-naive advanced clear cell RCC.
NCT06026410 - Conference Presentation
Cabaletta's rese-cel gMG data due in H2 2026, months after AAN preview
The RESET-MG trial's complete Phase 1/2 dataset is coming after a partial April 2026 presentation showed clinical responses in most evaluable patients, setting up whether the full cohort holds up.
NCT06359041 - Conference Presentation
Immunocore heads toward H2 2026 dose data on second PRAME bispecific
IMC-P115C's Phase 1 safety and tolerability readout, expected in the second half of 2026, will test whether Immunocore's half-life-extended PRAME candidate can extend a franchise built on brenetafusp.
NCT07156136 - Conference Presentation
Compass sets up full COMPANION-002 data unveil after tovecimig hit ORR, PFS
Compass Therapeutics will present the complete COMPANION-002 dataset, including duration of response, later in 2026, building on an already-disclosed 17.1% response rate and a 56% reduction in progression risk for tovecimig in second-line biliary tract cancer.
NCT05506943 - Conference Presentation
Tenaya to present two-year TN-201 gene therapy data in HCM in H2 2026
MyPEAK-1's planned late-2026 update will extend safety and MyBP-C biomarker signals already reported from a 7-patient dose-finding cohort in a trial with no direct clinical competitor.
NCT05836259 - Conference Presentation
Biogen to detail salanersen Phase 1b data as Phase 3 program advances behind it
Salanersen already showed 75% NfL reductions and new motor milestones in gene-therapy-experienced children, and Biogen just won Breakthrough Therapy Designation on that basis.
NCT05575011 - Conference Presentation
Apogee's asthma antibody already showed FeNO cuts; more data due in H2
A 31-patient Phase 1b trial already reported interim FeNO suppression and a favorable safety readout; Apogee plans to add more zumilokibart asthma data at medical conferences by year end.
NCT06920901 - Conference Presentation
Leads Biolabs to present LBL-024 first-line NSCLC cohort data in September
The PD-L1/4-1BB bispecific, already headed toward a BLA in another cancer, faces its first large first-line lung cancer readout as the Phase 2 trial keeps enrolling toward a December 2026 completion.
NCT06783647 - Conference Presentation
4DMT to show 4D-150's two-year wet AMD data ahead of pivotal readouts
PRISM's Phase 2b two-year results, due at a scientific conference in Q3 2026, will be the most mature look yet at 4D-150 before 4FRONT-1 topline data lands in H1 2027.
NCT05197270 - Conference Presentation
Immunome to detail RINGSIDE's 84% progression-risk cut for varegacestat at ASCO
The Phase 3 desmoid tumor trial already met its primary endpoint; Immunome filed an NDA in April and will present full data as it awaits FDA review.
NCT04871282 - Conference Presentation
Immix's NXC-201 hits 95% complete response rate ahead of September update
NEXICART-2's interim data show 19 of 20 evaluable AL amyloidosis patients converted to complete response, with the next update due in September testing whether that rate holds as more patients mature.
NCT06097832 - Conference Presentation
SonoClear device data on tumor-margin imaging head to EANS in October
A pivotal multicenter study of SonoClear's acoustic coupling fluid, which carries FDA Breakthrough Device status, will be presented at a European neurosurgery congress ahead of a still-pending US clearance.
NCT04734444 - Conference Presentation
Nanoscope to show 3-year MCO-010 data as BLA sits with FDA
The ASRS presentation adds durability follow-up to a trial that already reported its primary result, arriving after Nanoscope says it has submitted a BLA for the gene therapy in retinitis pigmentosa.
NCT04945772